Chemomab Therapeutics Files 20-F, Reports Capital Losses
Ticker: CMMB · Form: 20-F · Filed: Apr 4, 2025 · CIK: 1534248
| Field | Detail |
|---|---|
| Company | Chemomab Therapeutics LTD. (CMMB) |
| Form Type | 20-F |
| Filed Date | Apr 4, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 20-F, financials, capital-losses
TL;DR
Chemomab 20-F filed: $14.2M capital loss, valuation allowance needed.
AI Summary
Chemomab Therapeutics Ltd. filed its 20-F report for the fiscal year ending December 31, 2024. The company, formerly known as Anchiano Therapeutics Ltd. and BioCancell Ltd., is based in Tel Aviv, Israel. The filing details financial information, including capital losses of approximately $14,224 thousand for which a valuation allowance will be created.
Why It Matters
This annual filing provides investors with a comprehensive overview of Chemomab Therapeutics' financial health and operational status for the past fiscal year, impacting investment decisions.
Risk Assessment
Risk Level: medium — The filing mentions significant capital losses and the creation of a valuation allowance, indicating potential financial challenges.
Key Numbers
- $14.2B — Capital Losses (Significant losses reported for the fiscal year ending 12/31/2024, requiring a valuation allowance.)
- 20241231 — Fiscal Year End (The period covered by the 20-F filing.)
Key Players & Entities
- Chemomab Therapeutics Ltd. (company) — Filer of the 20-F report
- Anchiano Therapeutics Ltd. (company) — Former name of Chemomab Therapeutics Ltd.
- BioCancell Ltd. (company) — Former name of Chemomab Therapeutics Ltd.
- 14,224 thousands (dollar_amount) — Capital losses reported
FAQ
What is the total amount of capital losses reported by Chemomab Therapeutics Ltd. for the fiscal year ending December 31, 2024?
The company reported capital losses of approximately $14,224 thousand.
What action will Chemomab Therapeutics Ltd. take regarding the reported capital losses?
The company will create a full valuation allowance for these capital losses.
What is the SEC file number for this 20-F filing?
The SEC file number is 001-38807.
When was Chemomab Therapeutics Ltd. formerly known as Anchiano Therapeutics Ltd.?
The name change from Anchiano Therapeutics Ltd. to Chemomab Therapeutics Ltd. occurred on September 6, 2018.
What is the relationship between an American Depositary Share (ADS) and Ordinary Shares for Chemomab Therapeutics Ltd.?
One American Depositary Share (ADS) represents 20 Ordinary Shares.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on April 4, 2025 regarding Chemomab Therapeutics Ltd. (CMMB).